Dornase alfa: A new option in the management of cystic fibrosis

Pharmacotherapy

Volumn 16, Issue 1 I, 1996, Pages 40-48

  Witt, Daniel M ^a   Anderson, Leigh ^b  

^a Kaiser Permanente of Colorado ^*  (United States)

^b Multum Information Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA;

CLINICAL TRIAL; CYSTIC FIBROSIS; DNA DEGRADATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LARYNX DISORDER; REVIEW; SORE THROAT;

ADMINISTRATION, INHALATION; ADULT; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXPECTORANTS; HUMANS; RECOMBINANT PROTEINS;

EID: 0030024897     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Bosso JA. Cystic fibrosis. In: DiPiro JT, Talbert RL, Hayes PE, Yee CC, Matzke GR, Posey ML, eds. Pharmacotherapy, a pathophysiologic approach Norwalk, CT: Appleton & Lange, 1993:1183-94.
2. Davis PB. Evolution of therapy for cystic fibrosis. N Engl J Med 1994;331:672-3.
3. Franz MN, Cohn RC, Wachnowsky-Diakiw DM, Spohn WA. Management of children and adults with cystic fibrosis: one center's approach Hosp Formulary 1994;29:364-78.
4. Bosso JA. Advances in the pharmacotherapy of cystic fibrosis. J Clin Pharm Ther 1992;17:263-70.
5. McEvoy GK, Litvak K, Welsh OH, et al, eds. AHFS drug information 1994, supplement A. Bethesda, MD: American Society of Hospital Pharmacists, 1994:6-8.
6. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-92.
7. Genentech. Dornase alfa (Pulmozyme) package insert. San Francisco, 1993.
8. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safely of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-51.
9. Aitken ML, Burke W, McDonald C, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase I study. JAMA 1992,267:1947-51.
10. Hubbard RC, McElvaney NG, Birrer P, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992;326:812-15.
11. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
12. Rubin BK. Aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis [letter]. N Engl J Med 1992;327:571.
13. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331.637-42.
14. Anonymous. FDC reports, the pink sheet. October 31, 1994
15. Shah PL, Scott SF, Geddes D, et al. A preliminary report on using aerosolized recombinant human DNase I in the treatment of patients with stable stage cystic fibrosis for six months [abstr]. Pediatr Pulmonol 1993;suppl 9:247
16. Bryson HM, Sorkin EM. Dornase alfa: a review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994;48:894-906.
17. Balzer R, Corkery K, Sinicropi D, et al. Evaluation of occupational exposure to rhDNase [abstr]. Pediatr Pulmonol 1992;suppl 8:254.
18. Ramsey BW, Dorkin HL. Consensus conference: practical application of pulmozyme. Pediatr Pulmonol 1994;17:404-8.
19. Anonymous. The red book Montvale, NJ: Medical Economics, 1995.398.
20. Anonymous. Weekly pharmacy reports, the green sheet. 1994;43(3).
21. Anonymous. Aerosolized deoxyribonuclease for cystic fibrosis. Med Lett Drugs Ther 1994;36:34-5.
22. Anonymous. DNase shows potential for acute chronic bronchitis. Hosp Formulary 1994;29:494.
23. Anonymous. FDC reports, the pink sheet. July 17, 1995.
24. Shak S. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 1995;107(suppl 2):65S-70